StreetAlpha.app
Home › Stocks › IMNM

Immunome Inc. (IMNM)

Healthcare
$17.18
▼ −2.44%
LAST CLOSE · NOV 17

Immunome develops targeted cancer therapies, with a focus on antibody drug conjugates and an investigational treatment for desmoid tumors. It last closed at $17.18 on Nov 17, down 2.44% on the day. The average 12-month price target from 3 analysts is $28.33 (+64.9% from the last close), with a high of $32.00 and a low of $23.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $1.4M, the largest $1.4M.

AI Auto Pilots
Is IMNM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$282.6M
EPS (diluted)
−$2.63
Free cash flow
−$238.7M
Valuation
Market cap
$2.0B
118.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$212.8M
At Sep 30
Shareholder equity
$454.3M
Shares outstanding
118.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$10K−$10KFY2021FY2022: $5K$5KFY2022FY2023: $14.0M$14.0MFY2023FY2024: $9.0M$9.0MFY2024FY2025: $6.9M$6.9MFY2025

From IMNM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
3firms
2 Buy1 Hold0 Sell
Each firm's latest rating on IMNM in the past 90 days
Average 12-month target
$28.33
▲ 64.9% upside

Based on 3 analysts who set a price target on IMNM in the past 90 days. The average target is $28.33, with a high of $32.00 and a low of $23.00, compared with the last close of $17.18.

Low $23.00Avg $28.33High $32.00
Blue marker: last close $17.18
Highest target$32.00
Average target$28.33
Lowest target$23.00
Latest rating changes
StifelTarget lowered
Nov 10Hold$24 → $23
Piper SandlerMaintained
Nov 10Buy$30
StifelInitiated
Oct 1Hold$24
Alliance Global PartnersInitiated
Sep 21Buy$32
Truist SecuritiesTarget raised
Aug 12Buy$37 → $38
DateFirmActionRatingPrice target
Nov 10StifelTarget loweredHold$24 → $23
Nov 10Piper SandlerMaintainedBuy$30
Oct 1StifelInitiatedHold$24
Sep 21Alliance Global PartnersInitiatedBuy$32
Aug 12Truist SecuritiesTarget raisedBuy$37 → $38
Loading…

Technical Analysis

IMNM · as of the Nov 17 close · updated after every close
Downtrend

The stock is 8% below its 20 day and 18% below its 50 day average. It is 29% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $16.59, and the nearest resistance the Pivot at $17.37.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.4%/day
Key levels
$30.0652 week high+75.0%
$22.65100 day average+31.8%
$22.13200 day average+28.8%
$20.2850 day average+18.0%
$18.5820 day average+8.1%
$18.44Swing high (Oct 21)+7.3%
$17.97Pivot R1+4.6%
$17.37Pivot+1.1%
$17.18Last close
$16.59Pivot S1−3.4%
$16.4152 week low−4.5%
$16.41Swing low (Oct 16)−4.5%
Indicators
RSI (14)38.62Weak, oversold below 30Neutral
MACD-0.52Above its signal lineBullish
Stochastic13.4Near the bottom of its rangeOversold
ADX (14)21.4Weak trend
Williams %R-93.3Oversold below −80, overbought above −20Oversold
CCI (20)-160.0Oversold below −100, overbought above 100Oversold
Rate of change−15.4%Change over 10 sessionsBearish
ATR (14)$1.27Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMNM

What happened before

See how IMNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMNM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMNM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IMNM in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$1.4M
Largest print
$1.4M
Loading…

IMNM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●101 buying vs 94 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding211204+3.4%
In funds' top 10660.0%
Held by funds101.6%100.0%+1.6 pts
New / increased30 / 7130 / 77−5.6%
Reduced / sold out71 / 2362 / 27+5.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMNM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMNM is in one of them and how their past IMNM trades turned out.

IMNM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMNM in an article yet. Here's the latest on the wider market.

About Immunome

Immunome is a biotechnology company based in Bothell, Washington, that develops targeted cancer treatments. Its main focus is antibody drug conjugates, a type of therapy that carries cancer fighting drugs to tumor cells, along with other oncology therapies. Its lead candidate, varegacestat, is an investigational oral treatment for desmoid tumors, a rare connective tissue tumor. The company aims to serve cancer patients and the doctors who treat them.

Headquarters
Bothell, WA